Myriad Genetics, Inc.
NASDAQ:MYGN 10:02:23 AM EDT
| Market Cap (Intraday) | 1.67B |
| Current PE | N/A |
| Forward PE | 618.33 |
| 2yr Forward PE | 71.35 |
| 10-Day MA | $19.34 |
| 50-Day MA | $21.53 |
| 200-Day MA | $19.26 |
Myriad Genetics, Inc. Stock, NASDAQ:MYGN
322 North 2200 West, Salt Lake City, Utah 84116
United States of America
Phone: +1.801.584.3600
Number of Employees: 2700
Description
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk of developing a disease later in life. The Other segment offers testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.